+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

2019 Muscular Dystrophy Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767877
  • Report
  • 197 pages
  • VPA Research
1 of 4

FEATURED COMPANIES

  • aTyr Pharma Inc
  • Bio Blast Pharma Ltd
  • Genethon SA
  • GlaxoSmithKline Plc
  • Ionis Pharmaceuticals Inc
  • Medtronic Plc
  • MORE
The global clinical trial report- “2019 Muscular Dystrophy Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Muscular Dystrophy. It presents in-depth analysis of Muscular Dystrophy clinical trials across markets and companies. The research work is for providing complete understanding into trends in Muscular Dystrophy.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Muscular Dystrophy clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Muscular Dystrophy

The research work is prepared through extensive and continuous research on Muscular Dystrophy trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Muscular Dystrophy patients are identified
  • The report includes panorama of Muscular Dystrophy clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Muscular Dystrophy clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • aTyr Pharma Inc
  • Bio Blast Pharma Ltd
  • Genethon SA
  • GlaxoSmithKline Plc
  • Ionis Pharmaceuticals Inc
  • Medtronic Plc
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Muscular Dystrophy Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Muscular Dystrophy Clinical Trials by Region
2.2.2 Average Enrollment of Muscular Dystrophy Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Muscular Dystrophy Treatment, 2019

3. Region wise Muscular Dystrophy Clinical Trials
3.1 Asia Pacific Muscular Dystrophy Clinical Trials by Country
3.2 Europe Muscular Dystrophy Clinical Trials by Country
3.3 North America Muscular Dystrophy Clinical Trials by Country
3.4 Middle East and Africa Muscular Dystrophy Clinical Trials by Country
3.5 South and Central America Muscular Dystrophy Clinical Trials by Country

4. Muscular Dystrophy Clinical Trial Trends
4.1 Start Year wise Muscular Dystrophy Clinical Trials
4.2 Phase wise Muscular Dystrophy Clinical Trials
4.3 Trial Status wise Muscular Dystrophy Clinical Trials
4.4 Trial Type wise Muscular Dystrophy Clinical Trials

5. Muscular Dystrophy Average Enrollment Trends
5.1 Average Enrollment in Muscular Dystrophy Trials by Year
5.2 Average Enrollment in Muscular Dystrophy Trials by Phase
5.3 Average Enrollment in Muscular Dystrophy Trials by Status
5.4 Average Enrollment in Muscular Dystrophy Trials by Type of Trial

6. Companies Participating in Muscular Dystrophy Clinical Trials
6.1 Muscular Dystrophy Trials by Sponsor Type
6.2 Muscular Dystrophy Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Muscular Dystrophy Trials- Phase 1
7.2 Muscular Dystrophy Trials- Phase 2
7.3 Muscular Dystrophy Trials- Phase 3
7.4 Muscular Dystrophy Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Muscular Dystrophy Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Muscular Dystrophy Clinical Trials and Enrolment
Figure 5: Europe - Country wise Muscular Dystrophy Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Muscular Dystrophy Clinical Trials and Enrolment
Figure 7: North America - Country wise Muscular Dystrophy Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Muscular Dystrophy Clinical Trials and Enrolment
Figure 9: Muscular Dystrophy Clinical Trials by Phase
Figure 10: Muscular Dystrophy Clinical Trials by Trial Status
Figure 11: Muscular Dystrophy Clinical Trials by Type
Figure 12: Muscular Dystrophy Clinical Trials by Sponsor Type
Figure 13: Muscular Dystrophy Clinical Trials by Leading Sponsors
Figure 14: Muscular Dystrophy Average Enrollment by Phase
Figure 15: Muscular Dystrophy Average Enrollment by Trial Status
Figure 16: Muscular Dystrophy Average Enrollment by Type
Figure 17: Muscular Dystrophy- Average Enrolment by Type of Sponsors
Figure 18: Muscular Dystrophy- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Muscular Dystrophy Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Muscular Dystrophy Clinical Trials and Enrolment
Table 5: Europe - Country wise Muscular Dystrophy Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Muscular Dystrophy Clinical Trials and Enrolment
Table 7: North America - Country wise Muscular Dystrophy Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Muscular Dystrophy Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Muscular Dystrophy Average Enrollment by Phase
Table 15: Muscular Dystrophy Average Enrollment by Trial Status
Table 16: Muscular Dystrophy Average Enrollment by Type
Table 17: Muscular Dystrophy- Average Enrolment by Type of Sponsors
Table 18: Muscular Dystrophy- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • aTyr Pharma Inc
  • Bio Blast Pharma Ltd
  • BioMarin Pharmaceutical Inc
  • Genethon SA
  • GlaxoSmithKline Plc
  • Ionis Pharmaceuticals Inc
  • Medtronic Plc
  • Pfizer Inc
  • Prosensa Holding B.V.
  • PTC Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4767877
Adroll
adroll